Turnstone Biologics Corp

TSBX

Company Profile

  • Business description

    Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient’s own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient’s tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

  • Contact

    9310 Athena Circle
    Suite 300
    La JollaCA92037
    USA

    T: +1 347 897-5988

    https://www.turnstonebio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    81

Stocks News & Analysis

stocks

Vote in favour of merger for undervalued ASX share

We recommend shareholders vote in favor of its proposed merger.
stocks

Are investors missing the boat on this future ASX leader?

The market is underestimating the clear path to profitability.
stocks

ASX shares plunge but remain undervalued

Shares drop 17% after guidance is revised but we still see value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,569.10112.301.33%
CAC 407,623.38148.791.99%
DAX 4020,611.4136.730.18%
Dow JONES (US)43,221.55703.271.65%
FTSE 1008,359.1958.060.70%
HKSE19,522.89236.821.23%
NASDAQ19,511.23466.842.45%
Nikkei 22538,572.60128.020.33%
NZX 50 Index13,000.6757.100.44%
S&P 5005,949.91107.001.83%
S&P/ASX 2008,327.00113.701.38%
SSE Composite Index3,236.038.920.28%

Market Movers